In this webinar on May 27th, we will explore how signal peptide engineering is emerging as a powerful strategy to improve mRNA therapeutics.
January 12, 2026
Avenue Biosciences raises $5.7M to scale the first platform modulating the secretory pathway for enhanced therapeutic protein manufacturing
June 11, 2025
Avenue Biosciences Selected for 2025 BioTools Innovator Accelerator Program
May 20, 2025
Veli-Pekka Jaakola joins Avenue Biosciences as Chief Technology Officer
October 22, 2024
Avenue Biosciences Raises $2.5M Seed to Scale AI-Enhanced Protein Engineering
October 7, 2024
Avenue Biosciences Welcomes Industry Experts to Advisory Board for Market Insights and Focused Growth
October 4, 2024
Avenue Biosciences Joins StartX, the Largest Community of Stanford Founders
Using signal peptides to enhance expression of de novo-designed proteins
In this blog, we examine how signal peptide engineering can address challenges in the expression of de novo-designed proteins.
Leveraging signal peptides for smarter mRNA design
Advances in high throughput signal peptide analysis and computational models are creating new possibilities for smarter mRNA design.
Signal peptides – a significantly underutilized element in protein engineering
Despite existing in hundreds of thousands and expressing significant diversity, signal peptides have largely remained unexplored in commercial protein engineering. This is a missed opportunity as almost all therapeutic proteins and mRNA therapies contain a signal peptide that can be engineered for optimized production and functionality.
Meet us at PEGS Europe 2024
PEGS Europe, a biologics technology conference will be held in Barcelona, on November 5-7. Join our talk on November 6 by CEO Tero-Pekka Alastalo on optimizing protein expression with signal peptides.